24 TWENTYFOURSEVENBIOPHARMA Issue 2 / June 2025 BIO INTERNATIONAL CONVENTION What new products or innovations is your company showcasing at BIO 2025 this year? Kevin Schaab: Quotient Sciences, a global integrated CRDMO, is focusing on our continued innovation and expertise for clients across drug development, supporting flexible clinic and CMC strategies. This includes strong experience in conducting first in human trials in both the UK and US, our approach to integrated clinical testing with drug product manufacturing applied with our Translational Pharmaceutics platform, and drug product scale up and commercial manufacturing. Robert Cornog: We recently completed enhancements at our Philadelphia facility, located in Boothwyn, PA, to expand capacities for potent drug handling. Converting a portion of the existing manufacturing space into state-of-the-art potent compound drug product manufacturing areas has allowed our teams to add capacity for operations, increase safety and continue our commitment to quality for our multi-product commercial facility. We look forward to discussing planned future enhancements with our clients which will add greater support for even higher potency drug product manufacturing, expanding spray drying, and other capabilities in the future. What are you hoping to achieve from the event? Robert Cornog: BIO is always a great event to reconnect with new and existing clients. This year, I›m also looking forward to hearing about recent developments, applications and industry acceptance of Ai, digital tools and processes. Digitalization of information from the manufacturing floor and QC labs, up to patient monitoring using wearable devices, are allowing real world evidence and decisionmaking across the whole lifecycle of a drug—from development through manufacturing and delivery. Using that data for simulations and the creation of digital twins, which can be applied to advancing patient specific personalized medicine have the potential for changing the landscape. Kevin Schaab: BIO represents an opportunity to explore current developments across the multiple modalities now being leveraged to tackle unmet needs in medicine globally. It’s also a great chance to hear about innovative startups and technologies from across the industry. What challenges are you currently facing in the pharmaceutical market, and how is your organization addressing them? Robert Cornog: Like all companies, we›re continuing to monitor the impacts of recent BIOSECURE Act, FDA and NIH changes, and proposed US tariffs. We remain committed to supporting our pharma and biotech partners even in times of uncertainty, applying our expertise across drug development to save time and remove risk, particularly for rare disease and other programs seeking accelerated regulatory pathways. Kevin Schaab: With capabilities in both the US and the UK, we feel well-positioned to serve the needs of companies seeking CDMO/CRO partners in times of global uncertainty from a drug development perspective. What new products or innovations is your company showcasing at BIO 2025? At BIO, our team will be spotlighting our enhanced AbZelectPRO™ cell line development platform, which reduces gene-to-research-cell-bank timelines to ten weeks while sustaining >8g/L in high quality titers. We will also be promoting our next-gen ThioBridge™ conjugation technology for the precise design and delivery of dual-payload ADCs and emerging antibodyoligonucleotide conjugates (AOCs); and discussing our extensive expertise to support the development of complex bi and multi-specific drug programs. What are you hoping to achieve from the event? We aim to have productive meetings with customers that align our extensive CDMO+CRO capabilities with their project-specific needs, gather first-hand insight on pipeline priorities to refine our integrated discovery-to-commercial services, and introduce ourselves to new partners who are looking to rapidly progress their next-gen modalities to the clinic and beyond. How does your company stay ahead of industry trends and developments? Continuous platform R&D, sustained site investment, and cross-disciplinary advisory boards enable rapid advancements, such as our EpiScreen 2.0 immunogenicity suite, to de-risk our clients’ programs. Regular technology-horizon mapping ensures we anticipate modality shifts rather than react to them. What challenges are you currently facing in the pharmaceutical market, and how is your organization addressing them? Increased molecule complexity alongside uncertainties with legislation and supply chain have presented CAMPBELL BUNCE CSO Abzena
RkJQdWJsaXNoZXIy MjY2OTA4MA==